Search CommunityWalk:
Create_a_map_small
Mymaps_small



Blank

Avanti Therapeutics

Address:
20271 Goldenrod Lane
--
Germantown, MD, USA
1-202-642-5689

Category: Diagnostic/Imaging; Research Services & Supplies

Used in the following map:

Maryland Biotech Industry Map

Avanti Therapeutics is a biopharmaceutical company that applies its innovative drug development & commercialization platform to generate a pipeline of personalized medicine candidates to treat cancer and other difficult-to-treat diseases. Its vision is to provide powerful, immersive and innovative technology platform that bring simplicity, elegance, versatility and consistent quality to drug development.

Avanti's Aayush platform includes a complementary portfolio of personalized diagnostics, targeted therapeutics and reporters of efficacy to create novel disease-specific personalized medicine candidates. Its multifunctional nanoparticle based Aayush platform provides multiple patient friendly advantages to the innovative drugs developed through this technology, especially in terms of ease of use and cost. Its technology can be used to deliver a broad range of payloads including emerging therapeutic modalities such as antibodies, recombinant proteins, RNAi allowing the company to address multiple therapeutic areas and indications.

Avanti has developed a revolutionary new technology of creating multifunctional nanoparticles that are suitable for in vivo delivery of a potentially broad range of imaging agents, biomarkers and therapeutic drugs. Its nanobindi technology offers the ability to covert insoluble or poorly soluble drugs into delivery vehicles allowing them to become soluble and easier to deliver.
 
Avanti's product pipeline includes diagnostics, targeted therapeutics, reporters of therapeutic efficacy and biomarker monitoring. Using the proprietary platform, the company develops products for treatment areas – such as cancer, and cardiovascular diseases and central nervous system disorders. The company has completed number of proof of concept studies in major disease areas, including oncology, cardiovascular diseases, infectious diseases, CNS and regenerative medicine. Its products include: CT-K-124 for ovarian cancer, CT-PC-348 for pancreatic cancer, AT-AS-123 for atherosclerosis, AT-APD-617 for anti platelet drug, AT-ND-146 and AT-ND- 273 for neurodegenerative, AT-ML-147 for malaria, AT-IF-326 for influenza, AT-BR-279 for bone regeneration, etc.